Exclusive Summary

• The generic ticagrelor is US FDA GMP certified and launched in the US, providing a strong credential for market entry into most stringent regulatory markets worldwide, significantly reducing market access barriers and registration costs for overseas partners.
• Ticagrelor is a first-line drug recommended by guidelines for cardiovascular diseases, with a large patient base and stable market demand globally, ensuring continued market potential even after original patent expiry.
• The successful launch in the US demonstrates the company's capability in navigating complex regulatory and commercialization processes, making it highly attractive to partners seeking markets beyond the US.
• Compared to the originator drug, this generic offers a significant price advantage while maintaining equivalent quality and efficacy, addressing global healthcare cost containment and patient accessibility needs.
• Entering the market early or becoming a first generic in specific regions, especially where the generic ticagrelor landscape is not yet solidified, can secure a leading position and competitive advantage.